SEHK:1672Biotechs
Will Promising Preclinical Results in Obesity Candidates Reshape Ascletis Pharma's (SEHK:1672) Innovation Narrative?
Ascletis Pharma announced that its co-formulation of ASC36 and ASC35, two once-monthly next-generation peptide drug candidates, showed promising efficacy and chemical stability in preclinical obesity studies, with plans to submit an Investigational New Drug Application to the US FDA in the second quarter of 2026.
This advancement leverages Ascletis’ proprietary AI-assisted and ultra-long-acting drug technologies, aiming to address unmet needs in obesity treatment with differentiated dosing...